Buscar
Mostrando ítems 11-20 de 1014
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
(Nature Publishing Group, 2022)
Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Cancer nano-immunotherapy: the novel and promising weapon to fight cancer
(Mdpi Ag, 2024)
Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until today, continues to be a prevalent and lethal disease. Chemotherapy, radiotherapy, and surgery are ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Fruit and vegetable consumption is inversely associated with plasma saturated fatty acids at baseline in PREDIMED plus trial
(WILEY, 2021-07-17)
Scope: Plasma fatty acids (FAs) are associated with the development of cardiovascular diseases and metabolic syndrome. The aim of our study is to assess the relationship between fruit and vegetable (F&V) consumption and ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
(Public Library of Science, 2012-11-08)
Background: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-a2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report
(Frontiers Media S.A., 2023)
Nowadays, immune checkpoint inhibitors (ICI) have become the cornerstone of treatment for many tumors, either as monotherapy or in combination with other therapies. However, these drugs are associated with several new ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: the impact of cytomegalovirus disease and lymphopenia
(BMC, 2020)
Treatment of carbapenemase-producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
(BMC, 2018)
Background: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome
(Oxford University Press, 2021-12-09)
Autosomal dominant polycystic kidney disease (ADPKD) is the most widespread monogenic kidney disease, accounting for 5–10% of all end-stage kidney disease cases among adults. Tolvaptan, a highly selective non-peptide ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
(Elsevier, 2021-03)
Background and aims: Trial evidence for the benefits of cholesterol-lowering is limited for familial hypercho lesterolemia (FH) patients, since they have not been the focus of large outcome trials. We assess statin use in ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
(Nature Research, 2021-12-20)
Parkinson’s disease is a neurodegenerative movement disorder that currently has no disease-modifying treatment, partly owing to inefficiencies in drug target identification and validation. We use Mendelian randomization ...